Crenolanib
Overview[edit]
Crenolanib is a small molecule tyrosine kinase inhibitor that targets the platelet-derived growth factor receptor (PDGFR) and the FMS-like tyrosine kinase 3 (FLT3). It is primarily investigated for its potential use in treating various types of cancer, including acute myeloid leukemia (AML) and gastrointestinal stromal tumors (GISTs).
Mechanism of Action[edit]
Crenolanib functions by inhibiting the activity of PDGFR and FLT3, which are often overexpressed or mutated in certain cancers. By blocking these receptors, crenolanib can interfere with the signaling pathways that promote cancer cell proliferation and survival.
Clinical Applications[edit]
Acute Myeloid Leukemia[edit]
In acute myeloid leukemia, mutations in the FLT3 gene are common and are associated with poor prognosis. Crenolanib has shown promise in targeting these mutations, particularly the FLT3-ITD and FLT3-D835 mutations, which are resistant to other treatments.
Gastrointestinal Stromal Tumors[edit]
Crenolanib is also being studied for its efficacy in treating gastrointestinal stromal tumors, especially those that are resistant to other tyrosine kinase inhibitors like imatinib and sunitinib.
Pharmacokinetics[edit]
Crenolanib is administered orally and has a favorable pharmacokinetic profile, allowing it to be used in combination with other chemotherapeutic agents. Its ability to penetrate the central nervous system makes it a candidate for treating cancers with central nervous system involvement.
Side Effects[edit]
Common side effects of crenolanib include nausea, diarrhea, fatigue, and liver enzyme abnormalities. As with other tyrosine kinase inhibitors, careful monitoring of patients is necessary to manage these adverse effects.
Research and Development[edit]
Crenolanib is currently undergoing various clinical trials to evaluate its safety and efficacy in different cancer types. Ongoing research aims to optimize its use in combination therapies and to identify biomarkers that predict response to treatment.
Related Pages[edit]
- Tyrosine kinase inhibitor
- Acute myeloid leukemia
- Gastrointestinal stromal tumor
- Platelet-derived growth factor receptor
- FMS-like tyrosine kinase 3
Gallery[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
